Press Releases

• Successful further development of the product pipeline with conclusion of the patient enrollment for the IMPULSE study and the first phase of the TEACH study • Increase in R&D; expenses due to study progress • Successful capital...

The Supervisory Board of biotechnology company MOLOGEN AG (ISIN DE0006637200, Prime Standard of the Frankfurt Stock Exchange: MGN) today appointed Walter Miller as member of the Executive Board and new Chief Financial Officer (CFO) of MOLOGEN AG...

The biotech company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced today that the TEACH study with its immunomodulatory lefitolimod (MGN1703) in HIV patients will be extended as a result of the broad immune...

Berlin, 25 February 2016 – The biotech company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has...

Berlin, 20 January 2016 – The biotechnology company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) will present data on the immunotherapy MGN1703 at the 2016 Gastrointestinal Cancers Symposium (ASCO GI) in San...

Berlin, 19 January 2016 – The biotech company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) today announced that it has entered into a collaboration agreement with The University of Texas MD Anderson Cancer Center (MD...